Pharma deals reignite M&A boom

17 May 2016

In our weekly expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, examines a recent resurgence in M&A and questions whether it signals more activity later in 2016.

A succession of big pharma M&A deals in April, with Sanofi, AbbVie and Abbott bidding for Medivation, Stemcentrx and St Jude respectively, marked a surge of transactions in the sector totalling $45bn, following a pause in dealmaking in the first quarter of the year.

This resurgence of M&A activity in healthcare is fuelling hopes of a sustained boom. As we look to the latter half of the year, extrapolating from recent transactions and underlying drivers, 2016 looks set to continue to be a promising year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK